Inhibition of a complement regulator in vivo enhances antibody therapy in a model of mammary adenocarcinoma

International Journal of Cancer

Volumn 110, Issue 6, 2004, Pages 875-881

  Imai, Masaki ^a   Ohta, Rieko ^a   Okada, Noriko ^b   Tomlinson, Stephen ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Antibody therapy; Complement; Crry; Inhibitor

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CRRY; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DRUG DISTRIBUTION; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; CELL DIVISION; COMPLEMENT SYSTEM PROTEINS; CROSS REACTIONS; FEMALE; FLOW CYTOMETRY; MAMMARY NEOPLASMS, ANIMAL; RATS; RECEPTORS, COMPLEMENT; TISSUE DISTRIBUTION;

EID: 2942556518     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20178     Document Type: Article

References (36)

1. Koretz K, Bruderlein S, Henne C, Moller P. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. Br J Cancer 1992;66:810-4.
2. Kiso T, Mizuno M, Nasu J, Shimo K, Uesu T, Yamamoto K, Okada H, Fujita T, Tsuji T. Enhanced expression of decay-accelerating factor and CD59/homologous restriction factor 20 in intestinal metaplasia, gastric adenomas and intestinal-type gastric carcinomas but not in diffuse-type carcinomas. Histopathology 2002;40:339-47.
3. Li L, Spendlove I, Morgan J, Durrant LG. CD55 is over-expressed in the tumour environment. Br J Cancer 2001;84:80-6.
4. Hara T, Suzuki Y, Semba T, Hatanaka M, Matsumoto M, Seya T. High expression of membrane cofactor protein of complement (CD46) in human leukaemia cell lines: implication of an alternatively spliced form containing the STA domain in CD46 up-regulation. Scand J Immunol 1995;42:581-90.
5. Murray KP, Mathure S, Kaul R, Khan S, Carson LF, Twiggs LB, Martens MG, Kaul A. Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol 2000;76:176-82.
6. Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunology Today 1999;20:576-82.
7. Maio M, Brasoveanu LI, Coral S, Sigalotti L, Lamaj E, Gasparollo A, Visintin A, Altomonte M, Fonsatti E. Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and immunotherapy of human malignancies. Int J Oncol 1998;13:305-18.
8. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999;36:929-39.
9. Baranyi L, Baranji K, Takizawa H, Okada N, Okada H. Cell surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma. Immunology 1994;82:522-8.
10. Chen S, Caragine T, Cheung NK, Tomlinson S. CD59 expressed on a tumor cell surface modulates DAF expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res 2000;60:3013-118.
11. Caragine TA, Okada N, Frey AB, Tomlinson S. A Tumor-expressed Inhibitor of the early but not late lytic complement pathway enhances tumor growth in a rat model of human breast cancer. Cancer Research 2002;62:1110-15.
12. Blok VT, Daha MR, Tijsma O, Harris CL, Morgan BP, Fleuren GJ, Gorter A. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 1998;160:3437-43.
13. Gelderman KA, Kuppen PJ, Bruin W, Fleuren GJ, Gorter A. Enhancement of the complement activating capacity of 17-1A MAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur J Immunol 2002;32:128-35.
14. Harris CL, Kan KS, Stevenson GT, Morgan BP. Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59, cei 1997;107:364-71.
15. Takizawa H, Okada N, Okada H. Complement inhibitor of rat cell membrane resembling mouse Crry/p65. J.Immunol. 1994;152:3032-8.
16. Yu J, Abagyan RA, Dong S, Gilbert A, Nussenzweig V, Tomlinson S. Mapping the active site of CD59. J Exp Med 1997;185:745-53.
17. Yu J, Caragine T, Chen S, Morgan BP, Frey AF, Tomlinson S. Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59. Clin Exp Immunol 1999;115:13-8.
18. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM. Biodistribution and dose estimates for yttrium and iodine labeled monoclonal antibody IgG and fragments in nude in nude mice bearing human colonic tumor xenografts. Cancer Res 1990;50:2330-6.
19. Sharkey RM, Natale A, Goldenberg DM, Mattes MJ. Rapid blood clearance of immunoglobulin G2a and immunoglobulin G2b in nude mice. Cancer Res 1991;51:3102-7.
20. Caragine TA, Imai M, Frey AB, Tomlinson S. Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cell-mediated cytotoxicity. Blood 2002;100:3304-10.
21. Finberg RW, White W, Nicholson-Weller A. Decay accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol 1992;131:2913-8.
22. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W. Current protocols in immunology. In: Coico R, ed. Current protocols. Hoboken, NJ: John Wiley and Sons, Inc., 2002.
23. Miwa T, Nonaka M, Okada N, Wakana S, Shiroishi T, Okada H. Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1. Immunogenetics 1998;48:363-71.
24. Ong GL, Mattes MJ. Mouse strains with typical mammalian levels of complement activity. J Immunol Methods 1989;125:147-58.
25. Tanaka S, Suzuki T, Nishioka K. Assay of classical and alternative pathway activities of murine complement using antibody-sensitized rabbit erythrocytes. J Immunol Methods 1986;86:161-70.
26. Ebanks RO, Isenman DE. Mouse complement component C4 is devoid of classical pathway convertase subunit activity. J Immunol 1996;33:297-309.
27. Ooi YM, Colten HR. Genetic defect in secretion of complement C5 in mice. Nature 1979;282:207-8.
28. Bergman I, Basse PH, Barmada MA, Griffin JA, Cheung NK. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. Cancer Immunol Immunother 2000;49:259-66.
29. Hughes OD, Perkins AC, Frier M, Wastie ML, Denton G, Price MR, Denley H, Bishop MC. Imaging for staging bladder cancer: a clinical study of intravenous 11 lindium-labelled anti-MUC1 mucin monoclonal antibody C595. BJU Int 2001;87:39-46.
30. Hughes OD, Bishop MC, Perkins AC, Frier M, Price MR, Denton G, Smith A, Rutherford R, Schubiger PA. Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer. Eur J Nucl Med 1997;24:439-43.
31. Denton GS, Sekowski M, Spencer DI, Hughes OD, Murray A, Denley H, Tendler SJ, Price MR. Production and characterization of a recombinant anti-MUC1 scFv reactive with human carcinomas. Br J Cancer 1997;76:614-21.
32. Hughes OD, Bishop MC, Perkins AC, Wastie ML, Denton G, Price MR, Frier M, Denley H, Rutherford R, Schubiger PA. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. J Clin Oncol 2000;18:363-70.
33. Nakamura H, Hinoda Y, Nakagawa N, Makiguchi Y, Itoh F, Endo T, Imai K. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 1998;33:354-61.
34. Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 1998;46:245-52.
35. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000;18:574-83.
36. Rughetti A, Turchi V, Ghetti CA, Scambia G, Panici PB, Roncucci G, Mancuso S, Frati L, Nuti M. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 1993;53:2457-9.